This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +27.78% and +7.92%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
by Zacks Equity Research
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
by Zacks Equity Research
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 24.09% and 9.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 8.77% and 3.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
by Zacks Equity Research
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
by Zacks Equity Research
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall.
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
by Zacks Equity Research
WAT's first-quarter 2025 results reflect strong growth in the instruments and chemical segments, coupled with strong momentum in the industrial and pharma sectors.
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
by Zacks Equity Research
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025. Shares rise.
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
by Zacks Equity Research
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products.
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
XRAY is likely to have faced a tough first quarter with Byte's revenue loss, weak U.S. equipment demands and implant pressures.
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cigna Q1 Earnings Beat Estimates on Evernorth Health Strength
by Zacks Equity Research
CI increases adjusted earnings guidance for 2025 to $29.60 per share from the previous estimate of $29.50.